Crossmark

Evaluation of different standard and modified two-tier testing strategies for the laboratory diagnosis of lyme borreliosis in a European setting

Published Online: 2024-10-07

Published Print: 2024-12

Authors

Hoeve-Bakker, B. J. A. https://orcid.org/0000-0002-3872-3437
Kerkhof, K. https://orcid.org/0000-0002-2208-9902
Heron, M. https://orcid.org/0000-0003-0576-8652
Thijsen, S. F. T. https://orcid.org/0009-0000-8411-1653
van Gorkom, T. https://orcid.org/0000-0002-1565-5902
License Information

Text and Data Mining valid from 2024-10-07

Version of Record valid from 2024-10-07
More Information

Article History

Received: 30 April 2024

Accepted: 27 September 2024

First Online: 7 October 2024

Declarations

:

: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study “T-cell response in Lyme” (TRIL) was approved by the regional Medical Research Ethics Committees United (MEC-U), Nieuwegein, The Netherlands and registered with the Central Committee on Research Involving Human Subjects (CCMO) of the Netherlands under number NL36407.100.11 at 09–07-2020.

: Informed consent was obtained from all individual participants included in the TRIL study.

: The authors declare no competing interests.

Document is current